286 related articles for article (PubMed ID: 20850842)
21. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
23. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction.
Pinzani P; Lind K; Malentacchi F; Nesi G; Salvianti F; Villari D; Kubista M; Pazzagli M; Orlando C
Hum Pathol; 2008 Oct; 39(10):1474-82. PubMed ID: 18619642
[TBL] [Abstract][Full Text] [Related]
25. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
26. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Tsui KH; Feng TH; Chung LC; Chao CH; Chang PL; Juang HH
Anticancer Res; 2008; 28(4A):1969-76. PubMed ID: 18649734
[TBL] [Abstract][Full Text] [Related]
28. Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells.
Sica G; Zelano G; Settesoldi D; Iacopino F
Anticancer Res; 2003; 23(2B):1283-7. PubMed ID: 12820384
[TBL] [Abstract][Full Text] [Related]
29. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
[TBL] [Abstract][Full Text] [Related]
30. Current status of cardiac glycoside drug interactions.
Hooymans PM; Merkus FW
Clin Pharm; 1985; 4(4):404-13. PubMed ID: 2412751
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
[TBL] [Abstract][Full Text] [Related]
32. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter.
Chen H; Nandi AK; Li X; Bieberich CJ
Cancer Res; 2002 Jan; 62(2):338-40. PubMed ID: 11809674
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
Wang LG; Liu XM; Kreis W; Budman DR
Cancer Res; 1997 Feb; 57(4):714-9. PubMed ID: 9044850
[TBL] [Abstract][Full Text] [Related]
35. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
36. [Establishment of RNA interfering retrovirus vector targeting CXCR4 gene driven by human prostate-specific antigen promoter and its biological effects on prostate cancer cells].
Du YF; Xing YF; Zeng FQ; Lu P; Liu XY; Xiao YJ
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):489-94. PubMed ID: 18069626
[TBL] [Abstract][Full Text] [Related]
37. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P
Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098
[TBL] [Abstract][Full Text] [Related]
38. Regulation of prostate-specific antigen expression by the junctional adhesion molecule A.
Wang Q; Zheng JY; Kreth J; Yan X; Kamata M; Campbell RA; Xie Y; Chiu R; Berenson JR; Shi W; Chen IS; Pang S
Urology; 2009 May; 73(5):1119-25. PubMed ID: 18602143
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
